Clinical Trials Browser

Phase 2 × OTHER × Endometrial Neoplasms × Clear all

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 2 Recruiting

Recurrence, Endometrial Neoplasms

NCT05758688 2026-03-12

PROPS GYN

Phase 2 Recruiting

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03617679 2026-02-23

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Phase 2 Active not recruiting

79 enrolled 12 charts

Endometrial Neoplasms

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT07107334 2026-02-18

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Phase 2 Recruiting

Endometrial Hyperplasia, Endometrial Neoplasms

NCT04251416 2026-02-17

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05761951 2026-02-11

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Phase 2 Recruiting

Endometrial Neoplasms

NCT06925724 2026-02-10

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Phase 2 Recruiting

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT04774419 2026-02-03

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Phase 2 Recruiting

Endometrial Neoplasms

NCT07377734 2026-01-30

A Multicenter, Randomized, Open-Label, Controlled Clinical Trial of Intrauterine Injection of Recombinant Humanized Type III Collage in the Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

Phase 2 Not yet recruiting

Endometrial Hyperplasia, Endometrial Neoplasms

NCT07369986 2026-01-27

IMMUNE-SAVE

Phase 2 Not yet recruiting

Turcot syndrome, Endometrial Neoplasms

NCT05903131 2026-01-20

Uterine Preservation Via Lifestyle Transformation

Phase 2 Recruiting

GynecologicOther

Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT07139977 2026-01-20

EV-4-EC

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT07078838 2026-01-16

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

Phase 2 Not yet recruiting

GynecologicOther

Endometrial Hyperplasia, Hyperplasia, Obesity, Endometrial Neoplasms

NCT06129604 2026-01-15

Pilot Window of Opportunity Trial (POET)

Phase 2 Active not recruiting

GastrointestinalGynecologic

Colorectal Neoplasms, Endometrial Neoplasms

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2 Terminated

7 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT06518564 2026-01-07

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Phase 2 Recruiting

Endometrial Neoplasms

NCT03671811 2026-01-06

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

Phase 2 Active not recruiting

44 enrolled 12 charts

Endometrial Hyperplasia, Endometrial Neoplasms

NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03526432 2025-10-24

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT05036681 2025-09-17

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 8 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT07170982 2025-09-12

Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT04080284 2025-08-19

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Phase 2 Completed

Uterine Neoplasms, Endometrial Neoplasms

NCT07115927 2025-08-19

RODEO

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT02730429 2025-07-31

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT02730416 2025-07-29

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03832361 2025-07-18

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Phase 2 Recruiting

Endometrial Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2 Active not recruiting

106 enrolled 16 charts

Endometrial Neoplasms

NCT06942377 2025-07-08

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT04527900 2025-06-19

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

Phase 2 Terminated

Endometrial Neoplasms

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Endometrial Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT02899793 2025-06-11

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Phase 2 Completed

25 enrolled 15 charts

Endometrial Neoplasms

NCT06073184 2025-06-10

WE-FiERCE

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT03694262 2025-05-30

EndoBARR

Phase 2 Active not recruiting

30 enrolled 7 charts

Endometrial Neoplasms

NCT03835819 2025-05-15

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2 Active not recruiting

18 enrolled 17 charts

Endometrial Neoplasms

NCT05795244 2025-05-13

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Phase 2 Recruiting

Endometrial Neoplasms

NCT06914297 2025-04-30

TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

Phase 2 Recruiting

Endometrial Neoplasms

NCT06102863 2025-04-29

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Phase 2 Recruiting

Endometrial Hyperplasia, Endometrial Neoplasms

NCT05247268 2025-04-06

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Phase 2 Recruiting

Endometrial Neoplasms

NCT06502743 2025-04-03

PENELOPE

Phase 2 Recruiting

Endometrial Neoplasms